Lyra Therapeutics (NASDAQ:LYRA) Trading Down 15% – Time to Sell?

Lyra Therapeutics, Inc. (NASDAQ:LYRA)’s share price dropped 15% during trading on Wednesday . The company traded as low as $0.51 and last traded at $0.51. Approximately 15,603 shares were traded during trading, a decline of 72% from the average session volume of 56,719 shares. The stock had previously closed at $0.60.

Lyra Therapeutics Stock Down 15.0%

The stock has a 50-day moving average of $0.68 and a 200 day moving average of $1.27. The stock has a market cap of $905,250.00, a PE ratio of -0.02 and a beta of 0.68.

Institutional Trading of Lyra Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. DRW Securities LLC purchased a new stake in shares of Lyra Therapeutics in the 4th quarter valued at $52,000. Citadel Advisors LLC acquired a new position in shares of Lyra Therapeutics in the 3rd quarter worth approximately $128,000. Bank of America Corp DE lifted its holdings in shares of Lyra Therapeutics by 33.7% in the 2nd quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock worth $256,000 after acquiring an additional 7,190 shares during the last quarter. Artia Global Partners LP purchased a new position in shares of Lyra Therapeutics during the 4th quarter worth approximately $27,000. Finally, Sabby Management LLC boosted its position in shares of Lyra Therapeutics by 37.2% during the 4th quarter. Sabby Management LLC now owns 175,158 shares of the company’s stock worth $539,000 after purchasing an additional 47,534 shares during the period. 95.62% of the stock is currently owned by institutional investors and hedge funds.

Lyra Therapeutics Company Profile

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).